New ctDNA assay validated for minimal residual disease monitoring across solid tumors

◇ RESEARCH

The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low abundance. (J Mol Diagn)